NCT06401889

Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 25 (estimated)
• Sponsor: Mayo Clinic · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study evaluates changes in skin quality and self-esteem among breast cancer patients who are initiating aromatase inhibitor therapy.

Detailed description

PRIMARY OBJECTIVES: I. Evaluate the incidence and severity of skin quality changes after initiation of Aromatase Inhibitor (AI) therapy in breast cancer (BC) survivors through use of Canfield Sciences VISIA-CA technology and facial skin assessment photography. II. Evaluate impact of AI therapy on patient-reported self-esteem and dermatology related life quality through validated patient reported outcome measures. III. Assess for objective improvements in skin quality measurements with VISIA-CA after skincare intervention with aesthetician consultation. IV. Measure changes in patient-reported self-esteem and dermatology related life quality following skincare intervention. OUTLINE: This is an observational study. Patients complete surveys/questionnaires, undergo skin measurement with the VISIA CA device, undergo facial skin photography, and attend consultations with an aesthetician on study.

Conditions

• Anatomic Stage 0 Breast Cancer AJCC v8
• Anatomic Stage I Breast Cancer AJCC v8
• Anatomic Stage II Breast Cancer AJCC v8
• Anatomic Stage III Breast Cancer AJCC v8
• Breast Adenocarcinoma
• Estrogen Receptor-Positive Breast Carcinoma
• Progesterone Receptor-Positive Breast Carcinoma

Interventions

Type	Name	Description
OTHER	Non-Interventional Study	Non-interventional study

Timeline

• Start date: 2024-07-19
• Primary completion: 2027-07-19
• Completion: 2027-07-19
• First posted: 2024-05-07
• Last updated: 2026-03-30

Locations

1 site across 1 country: United States